Arcellx (ACLX) Competitors

Genmab A/S (NASDAQ:GMAB) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

Which has more risk & volatility, GMAB or ACLX?

Genmab A/S has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500.

Do analysts prefer GMAB or ACLX?

Genmab A/S currently has a consensus price target of $37.80, indicating a potential upside of 67.78%. Arcellx has a consensus price target of $114.31, indicating a potential upside of 62.60%. Given Genmab A/S's higher probable upside, equities analysts plainly believe Genmab A/S is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Arcellx	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.13

Which has better valuation and earnings, GMAB or ACLX?

Genmab A/S has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.63	$1.14B	$1.99	11.32
Arcellx	$107.94M	36.12	-$107.35M	-$3.42	-20.56

Is GMAB or ACLX more profitable?

Genmab A/S has a net margin of 37.53% compared to Arcellx's net margin of -329.93%. Genmab A/S's return on equity of 21.03% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	37.53%	21.03%	16.98%
Arcellx	-329.93%	-43.04%	-27.41%

Do institutionals & insiders have more ownership in GMAB or ACLX?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 96.0% of Arcellx shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 8.4% of Arcellx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media favor GMAB or ACLX?

In the previous week, Genmab A/S had 8 more articles in the media than Arcellx. MarketBeat recorded 23 mentions for Genmab A/S and 15 mentions for Arcellx. Genmab A/S's average media sentiment score of 1.09 beat Arcellx's score of 0.73 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	9 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcellx	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Arcellx on 11 of the 17 factors compared between the two stocks.